Aeterna Zentaris Inc., of Quebec City, reported that an article on final data for the phase I portion of the ongoing phase I/II trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and doxorubicin has been published in the December 2014 issue of Clinical Cancer Research.